These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
24. Does the medicating ADHD increase or decrease the risk for later substance abuse? Wilens TE Braz J Psychiatry; 2003 Sep; 25(3):127-8. PubMed ID: 12975683 [No Abstract] [Full Text] [Related]
25. Expert Opinion and Recommendations for the Management of Attention-Deficit/Hyperactivity Disorder in Correctional Facilities. Scott DA; Gignac M; Kronfli RN; Ocana A; Lorberg GW J Correct Health Care; 2016 Jan; 22(1):46-61. PubMed ID: 26672119 [TBL] [Abstract][Full Text] [Related]
26. Stimulant misuse in college for "pseudo-attention deficit disorder" during schizophrenia prodrome. Freudenreich O; Cather C; Holt D Am J Psychiatry; 2006 Nov; 163(11):2019. PubMed ID: 17074965 [No Abstract] [Full Text] [Related]
27. Methylphenidate-induced psychosis in adult attention-deficit/hyperactivity disorder: report of 3 new cases and review of the literature. Kraemer M; Uekermann J; Wiltfang J; Kis B Clin Neuropharmacol; 2010 Jul; 33(4):204-6. PubMed ID: 20571380 [TBL] [Abstract][Full Text] [Related]
28. Necessity for research directed at stimulant type and treatment-onset age to access the impact of medication on drug abuse vulnerability in teenagers with ADHD. Kantak KM; Dwoskin LP Pharmacol Biochem Behav; 2016 Jun; 145():24-6. PubMed ID: 27012495 [No Abstract] [Full Text] [Related]
29. Do stimulants prevent substance use and misuse among youth with attention-deficit/hyperactivity disorder? The answer is still maybe. Goldstein BI J Am Acad Child Adolesc Psychiatry; 2013 Mar; 52(3):225-7. PubMed ID: 23452678 [No Abstract] [Full Text] [Related]
30. A reply to critics of using stimulants to treat attention deficit hyperactivity disorder. Pliszka SR Tex Med; 1991 Apr; 87(4):84-7. PubMed ID: 1674631 [TBL] [Abstract][Full Text] [Related]
31. Abuse liability of medications used to treat attention-deficit/hyperactivity disorder (ADHD). Kollins SH Am J Addict; 2007; 16 Suppl 1():35-42; quiz 43-4. PubMed ID: 17453605 [TBL] [Abstract][Full Text] [Related]
32. Pharmacotherapy for attention-deficit/hyperactivity disorder (ADHD) decreases the risk for substance abuse: findings from a longitudinal follow-up of youths with and without ADHD. Biederman J J Clin Psychiatry; 2003; 64 Suppl 11():3-8. PubMed ID: 14529323 [TBL] [Abstract][Full Text] [Related]
37. FDA ponders cardiovascular risks of ADHD drugs. Young D Am J Health Syst Pharm; 2006 Mar; 63(6):492-4. PubMed ID: 16522874 [No Abstract] [Full Text] [Related]
38. Attention deficit hyperactivity disorder and substance use disorders: Is there a causal link? Lynskey MT; Hall W Addiction; 2001 Jun; 96(6):815-22. PubMed ID: 11399213 [TBL] [Abstract][Full Text] [Related]
40. Attention-deficit/hyperactivity disorder: the road traveled and the road ahead. Jun A Am J Health Syst Pharm; 2009 Nov; 66(22):2003. PubMed ID: 19890082 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]